|
|
|
Ac Immune Sa (NASDAQ: ACIU) |
|
Ac Immune Sa
ACIU's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Ac Immune Sa growth rates, revenue grew
in the fourth quarter of 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Ac Immune Sa net loss decreased from $-71 millions, to $-54 millions in fourth quarter of 2023,
• More on ACIU's Growth
|
|
Ac Immune Sa
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.68 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.13.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
• More on ACIU's Valuation
|
|
|
|
|
Ac Immune Sa
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.68 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.13.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
Ac Immune Sa Price to Book Ratio is at 1.12 lower than Industry Avg. of 35.1. and higher than S&P 500 Avg. of 0.01
• More on ACIU's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
